» Articles » PMID: 35793085

Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2022 Jul 6
PMID 35793085
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: The number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated persons, independent of the effect of reduced transmission, is a key measure of vaccine impact.

Objective: To estimate the number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated adults in the US.

Design, Setting, And Participants: In this modeling study, a multiplier model was used to extrapolate the number of SARS-CoV-2 infections and COVID-19-associated deaths from data on the number of COVID-19-associated hospitalizations stratified by state, month, and age group (18-49, 50-64, and ≥65 years) in the US from December 1, 2020, to September 30, 2021. These estimates were combined with data on vaccine coverage and effectiveness to estimate the risks of infections, hospitalizations, and deaths. Risks were applied to the US population 18 years or older to estimate the expected burden in that population without vaccination. The estimated burden in the US population 18 years or older given observed levels of vaccination was subtracted from the expected burden in the US population 18 years or older without vaccination (ie, counterfactual) to estimate the impact of vaccination among vaccinated persons.

Exposures: Completion of the COVID-19 vaccination course, defined as 2 doses of messenger RNA (BNT162b2 or mRNA-1273) vaccines or 1 dose of JNJ-78436735 vaccine.

Main Outcomes And Measures: Monthly numbers and percentages of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented were estimated among those who have been vaccinated in the US.

Results: COVID-19 vaccination was estimated to prevent approximately 27 million (95% uncertainty interval [UI], 22 million to 34 million) infections, 1.6 million (95% UI, 1.4 million to 1.8 million) hospitalizations, and 235 000 (95% UI, 175 000-305 000) deaths in the US from December 1, 2020, to September 30, 2021, among vaccinated adults 18 years or older. From September 1 to September 30, 2021, vaccination was estimated to prevent 52% (95% UI, 45%-62%) of expected infections, 56% (95% UI, 52%-62%) of expected hospitalizations, and 58% (95% UI, 53%-63%) of expected deaths in adults 18 years or older.

Conclusions And Relevance: These findings indicate that the US COVID-19 vaccination program prevented a substantial burden of morbidity and mortality through direct protection of vaccinated individuals.

Citing Articles

Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection.

Hurst J, Mohan A, Dalapati T, George I, Aquino J, Lugo D Nat Commun. 2025; 16(1):2383.

PMID: 40064870 PMC: 11894178. DOI: 10.1038/s41467-025-57655-3.


Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States.

Nyaku M, Yoon L, Ricci D, Rubens L, Sheridan P, Iyer M Vaccines (Basel). 2025; 13(2).

PMID: 40006713 PMC: 11861575. DOI: 10.3390/vaccines13020166.


COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years.

Yousaf A, Mak J, Gwynn L, Lutrick K, Bloodworth R, Rai R JAMA Netw Open. 2025; 8(2):e2459672.

PMID: 39992656 PMC: 11851240. DOI: 10.1001/jamanetworkopen.2024.59672.


COVID-19 clinical presentation, management, and epidemiology: a concise compendium.

Maison D, Tasissa H, Deitchman A, Peluso M, Deng Y, Miller F Front Public Health. 2025; 13:1498445.

PMID: 39957982 PMC: 11826932. DOI: 10.3389/fpubh.2025.1498445.


Management of a COVID-19 outbreak using a multidisciplinary approach and infection prevention control practices at a community living center in Veterans Administration Hospital, North Texas.

Oboho I, Hanna J, Silva-Rodriguez D, Christie-Smith A, Psenicka A, Khongmongkhon A Antimicrob Steward Healthc Epidemiol. 2025; 5(1):e12.

PMID: 39839361 PMC: 11748011. DOI: 10.1017/ash.2024.491.


References
1.
Andrejko K, Pry J, Myers J, Jewell N, Openshaw J, Watt J . Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clin Infect Dis. 2021; 74(8):1382-1389. PMC: 8406879. DOI: 10.1093/cid/ciab640. View

2.
Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen M . FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med. 2021; 2(8):979-992.e8. PMC: 8238652. DOI: 10.1016/j.medj.2021.06.007. View

3.
Tenforde M, Self W, Naioti E, Ginde A, Douin D, Olson S . Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(34):1156-1162. PMC: 8389395. DOI: 10.15585/mmwr.mm7034e2. View

4.
Tokars J, Rolfes M, Foppa I, Reed C . An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018; 36(48):7331-7337. PMC: 6666399. DOI: 10.1016/j.vaccine.2018.10.026. View

5.
Reese H, Iuliano A, Patel N, Garg S, Kim L, Silk B . Estimated Incidence of Coronavirus Disease 2019 (COVID-19) Illness and Hospitalization-United States, February-September 2020. Clin Infect Dis. 2020; 72(12):e1010-e1017. PMC: 7717219. DOI: 10.1093/cid/ciaa1780. View